Price Cuts On MS Drugs Lead UK's NICE To Reverse Earlier Rejection

10:36 EDT 14 May 2018 | Elsevier Business Intelligence

Avonex, Copaxone, Extavia and Rebif have all been recommended for use on England's National Health Service after their pr...

Original Article: Price Cuts On MS Drugs Lead UK's NICE To Reverse Earlier Rejection

More From BioPortfolio on "Price Cuts On MS Drugs Lead UK's NICE To Reverse Earlier Rejection"